A team of researchers at the Krembil Research Institute led by Drs. Charles Tator, Philippe Monnier and Andrea Mothe examined the potential role of a molecule known as RGMa. Their research showed that inhibiting RGMa activity in the SCI model produced several positive effects – it promoted the survival of nerve cells and the growth of their fibers near the site of injury, improved movement, coordination and mobility, and alleviated the pain that typically follows SCI.
If RGMa inhibition continues to produce promising results in the laboratory, the next step is clinical trials to establish if the treatment could benefit patients.
Find out more the spinal program at the Krembil Neuroscience Centre.